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T he largest experience with stem cell therapy in theheart has been with bone marrow mononuclear cells
(BMMCs). Several single-center studies have shown modest,
and in some cases transient, increases in ejection fraction
(EF) following BMMC injection in patients with reperfused
myocardial infarction.1 While this experience clearly demon-
strated the safety of BMMC injection, the imaging readouts
used in these phase 1 to 2 studies did not provide a clear
“stop or go” signal on which to base further decisions.
Several multicenter phase 3 studies of BMMC injection
were thus conducted and have been negative, showing no
signiﬁcant changes in EF.2,3 A clear need, therefore, exists
for more reﬁned imaging tools to guide the development of
regenerative therapies in the heart.
Successful regeneration in the heart requires the
injected cell to be delivered to the correct zone of the
myocardium, survive in the host microenvironment, exert
beneﬁcial paracrine effects, differentiate, and integrate with
the host myocardium. Advanced imaging techniques to
characterize many of these processes have been developed
(Figure) and several are poised for use in humans. In
the current issue of JAHA, Dash and colleagues add to
this armamentarium with an elegant approach involving
dual-contrast magnetic resonance imaging (MRI) and
positron emission tomography (PET) of a reporter probe.4
The value of this and other advanced imaging approaches is
discussed below.
Characterization of the Host Myocardium
Acute necrosis elicits an intense inﬂammatory response in
the myocardium.5,6 Highly degradative macrophages inﬁltrate
the infarct and release cytotoxic and proteolytic enzymes
including cathepsins, myeloperoxidase, and matrix metallo-
proteinases.7 Any cell that is injected, or migrates, into the
infarct zone must be able to survive in this highly hostile
inﬂammatory environment. MRI of iron-oxide nanoparticles
and PET imaging of 18ﬂuorodeoxyglucose can be used to
image the degree of macrophage inﬁltration in infarcted
myocardium.6 In addition, preclinical probes to myeloperox-
idase and matrix metalloproteinases have been developed for
MRI and nuclear imaging, respectively.7 Infarcted myocardium
has a poor vascular supply, limiting the availability of
nutrients and oxygen to any injected cells. The degree of
angiogenesis in healing infarcts has been imaged using a PET
tracer to the aVb3 integrin.
8 Imaging tools are thus available
to characterize the receptiveness of the host myocardium to
cell therapy and to personalize the timing and location of cell
injection.
The alternative to this image-guided approach is an empiric
strategy in which cells are injected at predeﬁned time points.
This formed the basis of the LateTIME trial, where cell
injection was performed 2 to 3 weeks after infarction.2
However, no advantage was seen in the delayed injection
strategy used in LateTIME. While this may reﬂect the inherent
limitations of BMMCs, the absence of an imaging readout to
characterize inﬂammation and angiogenesis in the myocar-
dium prior to cell injection may also have contributed to the
negative result.
Conﬁrmation of Local Cell Delivery
The delivery of cells to the myocardium must be conﬁrmed for
the analysis of the subsequent response to be interpreted in
its true context. A large body of preclinical experience exists
with MRI of the ferumoxides nanoparticle,9 which unfortu-
nately is no longer available. However, ferumoxytol is Food
and Drug Administration–approved and can be used for cell
labeling as well. The advantage of this cell-labeling approach
is that late gadolinium enhancement (LGE) of the infarct can
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Figure. Advanced imaging techniques in myocardial regeneration. Top row: (A) DNA release from acute necrosis (hyperenhanced area),
reproduced with permission from Huang et al5; (B) macrophage inﬁltration into the infarct (hypoenhanced area), reproduced with permission
from Sosnovik et al6; (C) MMP production (red) in the perfusion defect deﬁned by thallium (green), reproduced with permission from Su et al7;
(D) PET imaging of angiogenesis (arrows) in the healing infarct, reproduced with permission from Makowski et al8; Middle row: (E)
Intramyocardial injection of iron-oxide-labeled cells (arrows), reproduced with permission from Kraitchman et al9; (F) homing of radiolabeled
cells to the infarct (arrow), reproduced with permission from Kraitchman et al10; (G) PET imaging of embryonic stem cells expressing the
thymidine kinase reporter gene, reproduced with permission from Cao et al11; (H) MRI of the ferritin reporter gene producing signal
hypoenhancement (arrow), reproduced with permission from Naumova et al12; Bottom row: (I through K) DTI-tractography of ﬁbers in the lateral
wall of a normal mouse and a mouse with IR injury, reproduced with permission from Sosnovik et al.13 Fibers intersecting a standardized region-
of-interest (inset) are shown and are color-coded by their helix angle. After IR, coherent myoﬁber tracts can no longer be visualized in the apical
half of the ventricle. Serial in vivo imaging shows that ﬁber tracts that were present in the border zone preinjection (arrows) have been lost after
BMMC injection.13 BMMC indicates bone marrow mononuclear cell; DTI, diffusion tensor MRI; IR, ischemia–reperfusion; MMP, matrix
metalloproteinases; MRI, magnetic resonance imaging; PET, positron emission tomography.
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be simultaneously performed to further guide the location of
cell injection.9 Intravenous delivery of stem cells is more
challenging. The vast majority of the cells accumulate in the
liver, and radiolabeling is needed to detect cell delivery to the
myocardium.10 Concerns regarding the potential bioeffects of
radiolabeling are legitimate but can be mitigated in part by
labeling only a small fraction of the cells.
Assessment of Cell Survival and
Differentiation
An important caveat of all cell-labeling techniques is that the
presence of the label in the myocardium does not imply
survival of the cell. The label can persist in free form, or in
inﬂammatory cells, well after the death of the injected cell.
Dedicated approaches are needed to assess cell survival and
differentiation. Reporter genes encoding for bioluminescent,
ﬂuorescent, MR-detectable, and PET-detectable probes have
all been used to assess cell survival preclinically.11,12
Translation of the MR- and PET-based approaches is feasible,
but the injection of genetically manipulated cells is complex
and will require extensive testing. Ultimately, however, this
information will be crucial to understand the mechanism of
beneﬁt or mode of failure of any injected cell.
Generation and Alignment of New Myoﬁbers
The regeneration of infarcted myocardium requires new
myoﬁbers to be generated within the infarct. Moreover, these
myoﬁbers must be correctly aligned and integrated with the
surrounding myocardium. Diffusion Tensor MRI-tractography
allows myoﬁber architecture to be imaged noninvasively by
tracking the diffusion of water along myoﬁbers.13 Serial
in vivo imaging with the technique can be used to determine
whether new myoﬁbers are being regenerated and whether
they are spiraling around the left ventricle with the correct
helix angle.13 The difference in helix angle (120°) between
the subendocardial and subepicardial ﬁbers plays a key role in
the mechanical and electrical function of the heart and is vital
to replicate during regeneration.
Diffusion tensor MRI provides a direct and fundamental
measure of myoﬁber regeneration that is likely to be highly
predictive of downstream clinical response. Serial in vivo
diffusion tensor MRI-tractography in infarcted mice injected
with BMMCs revealed a neutral response,13 consistent with
the results of the TIME, LateTIME, and Swiss-AMI trials.2,3 In
addition, in occasional cases, the response to BMMC injection
was negative.13 Diffusion tensor MRI-tractography can be
performed in humans and could play a valuable role in early
clinical trials. One limitation of the technique, however, is its
inability to distinguish new myoﬁbers generated from endoge-
nous repair from those generated directly from the injected
cells. Reporter imaging approaches, capable of making this
distinction, will thus need to be developed.
Molecular and Metabolic Imaging of the
Myocardium
Molecular imaging techniques to follow many of the processes
involved in infarct healing and remodeling have been devel-
oped (Figure). Metabolic imaging with PET and MR spec-
troscopy can also provide important insights into the efﬁciency
of myocardial contraction after cell therapy. The use of 31P to
measure high-energy phosphates in the myocardium is well
established, and could potentially be combined with hyperpo-
larized 13C MRI and 11C PET in a multiplexed approach.
Myocardial Viability and Infarct Size
LGE is being increasingly used to detect a reduction in infarct
size following cell therapy.14 It is critical to understand,
however, what exactly is being imaged with LGE. Clinically
used gadolinium chelates cannot cross cell membranes and
accumulate nonspeciﬁcally in the extracellular space. Any
process that expands the extracellular space with thus lead to
an accumulation of gadolinium. In chronic infarction, the
correlation between LGE and infarct size is excellent.
However, in acute infarction the extent of LGE can overes-
timate infarct size, particularly in the border zones. Man-
ganese (Mn)-based contrast agents are transported through
calcium channels into viable cells and provide a speciﬁc
signature of cell viability. A loss of viability is characterized by
the absence of Mn uptake and deﬁnes an area that is
frequently smaller than that deﬁned by LGE.
In their elegant study, Dash and colleagues use the
difference between the areas deﬁned by LGE and the absence
of Mn uptake to deﬁne the peri-infarct zone (PIR).4 A reduction
in the size of the PIR through the generation of new myoﬁbers
is one of the central aims of cell therapy following acute
infarction. The response to intramyocardial injection of human
amniotic mesenchymal stem cells was examined in their
study. Cell injection decreased the size of the infarct core and
the PIR, and resulted in lower end-diastolic volumes and
higher EF.4 A strong correlation was seen between increased
viability in the PIR and cell survival via PET imaging of the
thymidine kinase reporter gene. However, consistent with
prior studies of mesenchymal stem cells, no evidence of
cardiomyocyte differentiation was seen.4
T1 mapping, both with and without gadolinium, is being
increasingly used to detect changes in the properties of the
myocardium, and the detection of myocardial edema with T2-
weighted imaging is widely used to detect the area-at-risk.
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How then do we interpret the dual-contrast technique
described by Dash and colleagues in the context of these
advances? While the combination of T2, T1, and gray zone
imaging with LGE could all conceivably detect changes in the
size of the PIR, they lack the speciﬁc signature of viability
provided by Mn uptake. One could thus potentially envisage a
scenario where Mn-based viability imaging, rather than LGE, is
used in conjunction with native T1 and T2 mapping to
characterize changes in the infarct zone and PIR after cell
therapy.
Conclusions
The early trials of stem cell therapy in the heart were based
largely on the measurement of EF by echocardiography, while
in later trials MRI was used. Interestingly, a meta-analysis of
BMMC trials revealed positive results by echo-derived EF and
negative results using MRI-derived EF.1 It would be a mistake,
however, to assume that the use of MRI, including LGE,
provides us with all the tools we need. The complexity of the
myocardium and of the regenerative process will require
advanced imaging techniques to be developed for optimal
results. As shown in the excellent article by Dash and
colleagues, the imaging community is rising to meet this
challenge.
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